Clinic Department of Orthopedic Surgery, Rochester, Minnesota, USA.
Mayo Clinic Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA.
J Surg Oncol. 2021 Jan;123(1):127-132. doi: 10.1002/jso.26262. Epub 2020 Oct 15.
Nonuterine leiomyosarcomas (LMS) are common extremity soft-tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS.
We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow-up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy.
The 10-year disease-specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10-year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10-year metastatic free survival (81% vs. 100%, p = .03).
The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.
非子宫平滑肌肉瘤(LMS)是常见的肢体软组织肉瘤。深部 LMS 复发风险增加;然而,很少有研究关注浅表 LMS。
我们回顾了 82 例原发性浅表 LMS 患者的临床病理特征。平均年龄和随访时间分别为 57±15 岁和 7±5 年。根据最终切除标本,将深度分为真皮(位于皮肤内;n=35,43%)和皮下(位于真皮以下、筋膜以上;n=47,57%)。真皮病例采用阴性切缘切除术治疗,而皮下肿瘤由多学科团队评估是否考虑辅助治疗。
浅表 LMS 的 10 年疾病特异性生存率(DSS)为 90%,真皮(100%)和皮下(86%)LMS 患者的 10 年 DSS 无差异(p=0.18)。所有疾病复发均发生在皮下 LMS(17%比 0%,p=0.02),且皮下肿瘤 10 年无转移生存率更差(81%比 100%,p=0.03)。
本研究结果表明,真皮 LMS 可单独采用阴性切缘切除术治疗。虽然皮下 LMS 患者的预后相当好,但存在局部和远处复发的风险,此类患者将受益于多学科治疗。